drugset

drugset / Trial / NCT00421135

A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer

NCT00421135 ↗

Phase 1 Completed 30 enrolled Alaunos Therapeutics

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study of safety of Isophosphoramide Mustard (IPM) in the treatment of advanced cancer.

Timeline

Start: 2006-02
Primary completion: 2007-10
Completion: 2007-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Palifosfamide	Small molecule	—	Intravenous

Indications